Home
Storia in 1 fonti
Sarepta tumbles as its gene therapy sales decline further
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
Raccontata da
biopharmadive.com
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
